CoChat

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Open access
Braun, David A., Bakouny, Ziad, Hirsch, Laure, Flippot, Ronan, Van Allen, Eliezer M., Wu, Catherine J., Choueiri, Toni K. · 2021 · Nature Reviews Clinical Oncology

The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.

Abstract

The management of advanced-stage renal cell carcinoma (RCC) has been transformed by the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not derive durable clinical benefit from these agents. Importantly, unlike other immunotherapy-responsive solid tumours, most RCCs have only a moderate mutational burden, and paradoxically, high levels of tumour CD8+ T cell infiltration are associated with a worse prognosis in patients with this disease. Building on the successes of antibodies targeting the PD-1 and CTLA4 immune checkpoints, multiple innovative immunotherapies are now in clinical development for the treatment of patients with RCC, including ICIs with novel targets, co-stimulatory pathway agonists, modified cytokines, metabolic pathway modulators, cell therapies and therapeutic vaccines. However, the successful development of such novel immune-based treatments and of immunotherapy-based combinations will require a disease-specific framework that incorporates a deep understanding of RCC immunobiology. In this Review, using the structure provided by the well-described cancer-immunity cycle, we outline the key steps required for a successful antitumour immune response in the context of RCC, and describe the development of promising new immunotherapies within the context of this framework. With this approach, we summarize and analyse the most encouraging targets of novel immune-based therapies within the RCC microenvironment, and review the landscape of emerging antigen-directed therapies for this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-020-00455-z

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 174 references

Cited by

See all 369

Metadata

Authors
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K.
Affiliations
  • Broad Institute (US)
  • Dana-Farber Cancer Institute (US)
  • Harvard University (US)
  • Institut Gustave Roussy (FR)
Corresponding author
Choueiri, Toni K.
Venue
Nature Reviews Clinical Oncology
Published
2021-01-12
Volume
18
Issue
4
Pages
199-214
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W3118419510
Cited by
356
References
173
Citations by year
2026: 37 · 2025: 50 · 2024: 61 · 2023: 89 · 2022: 74 · 2021: 45
FWCI
8.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA227388, P50CA101942, U01CA233100, R01CA155010, U24CA224331, P30CA006516)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
renal cell carcinoma, immune checkpoint inhibitors, cell therapy, therapeutic vaccines, tumor immune microenvironment, cancer-immunity cycle, PD-1, CTLA-4, tumor mutational burden, CD8+ T cell infiltration, immunotherapy resistance
MeSH terms
Immune Checkpoint Inhibitors, Carcinoma, Renal Cell, Humans, Immunologic Factors, Immunotherapy, Kidney Neoplasms, Drugs, Investigational, Therapies, Investigational

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41571-020-00455-z
The paper
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021). Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-020-00455-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.